Survivin and Her2 Expressions in Different Grades of Urothelial Neoplasms of Urinary Bladder

Abstract

Scan to discover online Background & Objective: Urothelial neoplasm (UN) of bladder is a potentially lethal malignancy, particularly in locally advanced or metastatic cases. Development of molecular markers such as HER2 and Survivin may provide useful information on diagnosis and prognosis in UN of bladder. Methods: We studied the immunohistochemical (IHC) expression of HER2 and Survivin in 84 radical/partial cystectomy and transurethral resection (TUR) specimens with different histologic grades and stages. All samples were obtained from Pathology Department of Sina Hospital in Tehran, Iran from 2014 to 2018.Results: From the total number of 84 UN samples, 10 cases (11.9%) showed papillary neoplasm of low malignant potential, 30 cases (35.7%) presented with lowgrade papillary urothelial neoplasm, and 44 cases (52.4%) diagnosed as high-grade papillary urothelial neoplasm. HER2 and Survivin expressions were seen in 44 (52.4%) (P=0.610) and 9 (10.7%) patients (P=0.046), respectively. Survivin expression showed a mild increase in high grade UN.Conclusion: Our findings suggest that the IHC expression of Survivin and HER2 are not well associated with histological grades of urothelial neoplasms of bladder. This may be partly due to relatively small sample size and other factors such as patient characteristics or antibody specifications.

Molecular Basis of Tumorigenesis of Bladder Cancer and Emerging Concepts in Developing Therapeutic Targets

“…Despite the prevalence of HER-2 expression alterations in many cancer types, only breast and gastric cancers benefit from targeting it, suggesting that more than altered expression is needed to settle for HER-2 targeting therapy [74][75][76][77][78]. Although studies correlating HER-2 expression and BUC behavior show conflicting results [79,80], Her-2 overexpression is a prognostic biomarker for recurrence and patient survival in NMIBC [81][82][83][84], but has not been a successful therapeutic target yet [85,86]. One case study had a complete response to trastuzumab+gemcitabine as a third-line treatment…”